FORMULATION OF ENTERIC GRANULES CONTAINING GREEN TEA (CAMELLIA SINENSIS) EXTRACT USING EUDRAGIT L100-55 AS A DELAYED RELEASE MATRIX
Keywords:Delayed release, Enteric, Epigallocatechin gallate, Eudragit L100-55, Granules, Green tea (Camellia sinensis) extract
Objective: Epigallocatechin gallate (EGCG) inhibits glucose absorption into the blood by inhibiting small intestinal α-glucosidase but is unstable in
gastric fluid. Hence, we formulated EGCG into enteric preparations that prevent release in gastric fluid.
Methods: Granules were prepared using a wet granulation method and were formulated into polyvinylpyrrolidone (PVP)-Eudragit L100-55 (5:1; F1),
PVP-Eudragit L100-55 (1:1; F2), and Eudragit L100-55 (F3) preparations using 30% w/w Eudragit L100-55 as a matrix. EGCG contents of granules
were evaluated and dissolution tests were performed at pH 1.2 and 6.8.
Results: F1–3 formulas had good flow properties and contained EGCG at 24.05%±0.15%–24.96%±0.28%. Dissolution tests showed that F1 and F2
formulas released EGCG at 50.53%±0.04% and 17.80%±0.55%, respectively, after 2 h in HCl medium at pH 1.2. Cumulative drug release from F1 and
F2 formulations after 2 h under these conditions (pH 1.2) and 1 h in phosphate buffer (pH 6.8) was 94.40%±1.58% and 93.70%±1.08%, respectively.
Conclusion: As the optimal formula, F3 granules limited drug release to 7.03%±0.22% in HCl at pH 1.2 over 2 h and cumulative drug release in HCl
medium (pH 1.2) followed by phosphate buffer (pH 6.8) of 86.13%±0.20%.
activity of isolated fractions from water extract of Qingzhuan dark tea.
BMC Complement Altern Med 2016;16:378.
2. Forester SC, Gu Y, Lambert JD. Inhibition of starch digestion by the
green tea polyphenol, (-)-epigallocatechin-3-gallate. Mol Nutr Food
3. Onoue S, Ochi M, Yamada S. Development of (-)-epigallocatechin-
3-gallate (EGCG)-loaded enteric microparticles with intestinal
mucoadhesive property. Int J Pharm 2011;410:111-3.
4. Zeng L, Ma M, Li C, Luo L. Stability of tea polyphenols solution with
different pH at different temperatures. Int J Food Prop 2016;20:1-8.
5. Lieberman H, Lachman L, Schwartz J. Pharmaceutical Dosage Forms.
New York: Marcel Dekker, Inc.; 1989.
6. Khutle NM, Pole S, Hasnak P, Rathod N, Bendale S. A Detail
understanding of enterik coated granul: Manufacturing and evaluation.
Eur J Pharm Med Res 2016;3:135-44.
7. Varshosaz J, Kennedy R, Gipps E. Use of enteric polymers for
production of microspheres by extrusion-spheronization. Pharm Acta
8. Rowe R. Handbook of Pharmaceutical Excipients. London, UK:
Pharmaceutical Press; 2009.
9. Rojas J, González C, Rico C, Saez O. Formulation of a modified
release metformin. HCL matrix tablet: Influence of some hydrophilic
polymers on release rate and in-vitro evaluation. Braz J Pharm Sci
10. Andrews G, Jones D, Diak O, McCoy C, Watts A, McGinity J. The
manufacture and characterisation of hot-melt extruded enteric tablets.
Braz J Pharm Sci 2008;69:264-73.
11. Cao Y, Teng J, Selbo J. Amorphous solid dispersion of epigallocatechin
gallate for enhanced physical stability and controlled release.
Pharmaceuticals (Basel) 2017;10:88.
12. Kotla NG, Singh S, Maddiboyina B, Sunnapu O, Webster TJ. A novel
dissolution media for testing drug release from a nanostructured
polysaccharide-based colon specific drug delivery system: An approach
to alternative colon media. Int J Nanomed 2016;11:1089-95.
13. Rahmawati I, Pribadi P, Hidayat I. Formulasi dan evaluasi granul
effervescent ekstrak daun binahong (Anredera cordifolia [Tenore]
Steen.). Pharmaciana 2016;6:139-48.
14. Wu Y, Li X, Che T, Zhu Z, Kang J. The United States Pharmacopoeia
35; The National Formulary 30. Rockville, Md: United States
Pharmacopeial Convention; 2012.
15. Fangueiro J, Parra A, Silva A, Egea M, Soutto E, Garcia M, et al.
Validation of a High performance liquid chromatography method for the
stabilization of epigallocatechin gallate. Int J Pharm 2014;475:181?90.